IL34 and autoimmune disease: Infliximab, a chimeric monoclonal antibody and a medication used, among others, to treat a number of autoimmune diseases, reduces the expression of the interleukin-34 (IL-34) involved in monocyte and macrophage differentiation, survival, and function [6–9].